These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 2547386

  • 1. L-6-ketopiperidine-2-carbonyl-L-leucyl-L-proline amide as a novel thyrotropin releasing hormone analogue with improving effects on impaired central nervous systems functions.
    Oka M, Ochi Y, Furukawa K, Ito T, Miura Y, Karasawa T, Kadokawa T.
    Arzneimittelforschung; 1989 Mar; 39(3):297-303. PubMed ID: 2547386
    [Abstract] [Full Text] [Related]

  • 2. Effects of thyrotropin-releasing hormone and its analogue L-6-ketopiperidine-2-carbonyl-leucyl-L-prolin-amide on behaviour and electroencephalogram.
    Sarkadi A, Szabo S, Laszy J, Ambrus A, Szporny L.
    Arzneimittelforschung; 1988 Aug; 38(8):1134-8. PubMed ID: 3143370
    [Abstract] [Full Text] [Related]

  • 3. Memory deficits following internal capsule lesions in rats and their improvement by L-6-ketopiperidine-2-carbonyl-L-leucyl-L-proline amide (RGH-2202), a thyrotropin-releasing hormone analogue.
    Oka M, Ito T, Furukawa K, Karasawa T, Kadokawa T.
    Arch Int Pharmacodyn Ther; 1990 Aug; 306():18-33. PubMed ID: 1981666
    [Abstract] [Full Text] [Related]

  • 4. Effects of the novel thyrotropin-releasing hormone analogue Na -((1S,2R)-2-methyl-4-oxocyclopentylcarbonyl)-L-histidyl-L-prol ina mide monohydrate on the central nervous system in mice and rats.
    Matsushita M, Yonemori F, Furukawa N, Ohta A, Toide K, Uchida I, Iwata K.
    Arzneimittelforschung; 1993 Aug; 43(8):813-7. PubMed ID: 8216433
    [Abstract] [Full Text] [Related]

  • 5. Antiepileptic potential and behavioral profile of L-pGlu-(2-propyl)-L-His-L-ProNH2, a newer thyrotropin-releasing hormone analog.
    Rajput SK, Krishnamoorthy S, Pawar C, Kaur N, Monga V, Meena CL, Jain R, Sharma SS.
    Epilepsy Behav; 2009 Jan; 14(1):48-53. PubMed ID: 18952198
    [Abstract] [Full Text] [Related]

  • 6. The effect of VA-045 on disturbance in consciousness in experimental animal models.
    Okuyama S, Imagawa Y, Ogawa S, Saito Y, Araki H, Otomo S, Sakagawa T, Yamada S, Shima K.
    Res Commun Chem Pathol Pharmacol; 1993 Oct; 82(1):91-100. PubMed ID: 8272576
    [Abstract] [Full Text] [Related]

  • 7. Behavioral changes induced by the thyrotropin-releasing hormone analogue, RGH 2202.
    Drago F, Grassi M, Valerio C, Coppi G, Lauria N, Nicotra GC, Raffaele R.
    Peptides; 1991 Oct; 12(6):1309-13. PubMed ID: 1815218
    [Abstract] [Full Text] [Related]

  • 8. Biological activity of TRH thionalogue and its diastereoisomers.
    Alexandrová M, Strbák V, Herman ZS, Stachura Z, Kruszyński M.
    Endocrinol Exp; 1987 Mar; 21(1):43-9. PubMed ID: 3106009
    [Abstract] [Full Text] [Related]

  • 9. Effects of RGH 2202 on cognitive and motor behavior of the rat.
    Drago F, Coppi G, Antonuzzo PA, Valerio C, Genazzani AA, Grassi M, Raffaele R, Scapagnini U.
    Neurobiol Aging; 1996 Mar; 17(1):67-71. PubMed ID: 8786805
    [Abstract] [Full Text] [Related]

  • 10. [TRH analogs at Gedeon Richter Ltd.: highlights of experimental and clinical efficacy of posatirelin].
    Sarkadi A, Kárpáti E.
    Acta Pharm Hung; 2002 Mar; 72(1):62-8. PubMed ID: 12426788
    [Abstract] [Full Text] [Related]

  • 11. Systemically applied thyrotropin-releasing hormone (TRH) modifies spontaneous behaviour of rats.
    Arnold R, Klingberg F, Schäker W.
    Biomed Biochim Acta; 1991 Mar; 50(12):1217-24. PubMed ID: 1824539
    [Abstract] [Full Text] [Related]

  • 12. Modification of dopaminergic transmission by thyrotropin-releasing hormone.
    Narumi S, Nagawa Y.
    Adv Biochem Psychopharmacol; 1983 Mar; 36():185-97. PubMed ID: 6305147
    [Abstract] [Full Text] [Related]

  • 13. Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motor deficits after chronic focal cerebral ischemia in rats.
    Yonemori F, Yamaguchi T, Nakayama H, Narita K, Hojo S, Tamura A.
    J Cereb Blood Flow Metab; 2000 Jan; 20(1):74-81. PubMed ID: 10616795
    [Abstract] [Full Text] [Related]

  • 14. Lack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in rats.
    Asai H, Asahi T, Yamamura M, Yamauchi-Kohno R, Saito A.
    Pharmacol Biochem Behav; 2005 Dec; 82(4):646-51. PubMed ID: 16368129
    [Abstract] [Full Text] [Related]

  • 15. Effects of a new TRH analogue, YM-14673, on spontaneous motor activity in rats.
    Shimizu M, Yamamoto M, Kobayashi M.
    Arch Int Pharmacodyn Ther; 1989 Dec; 301():100-11. PubMed ID: 2516440
    [Abstract] [Full Text] [Related]

  • 16. TRH analogue with C-terminal thioamide group: rapid degradation by plasma and its biological effects.
    Angyal R, Strbák V, Alexandrová M, Kruszyński M.
    Endocrinol Exp; 1985 Dec; 19(4):213-9. PubMed ID: 3002750
    [Abstract] [Full Text] [Related]

  • 17. Increase in rat regional brain cyclic nucleotides by thyrotropin-releasing hormone (TRH) and its analog DN-1417.
    Narumi S, Nagai Y, Saji Y, Nagawa Y.
    Jpn J Pharmacol; 1983 Oct; 33(5):915-26. PubMed ID: 6139495
    [Abstract] [Full Text] [Related]

  • 18. Effects of a new TRH analogue, YM-14673 on the central nervous system.
    Yamamoto M, Shimizu M.
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):561-5. PubMed ID: 3125485
    [Abstract] [Full Text] [Related]

  • 19. Effects of taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in rat brain.
    Fukuchi I, Asahi T, Kawashima K, Kawashima Y, Yamamura M, Matsuoka Y, Kinoshita K.
    Arzneimittelforschung; 1998 Apr; 48(4):353-9. PubMed ID: 9608876
    [Abstract] [Full Text] [Related]

  • 20. Effects of thyrotropin-releasing hormone on behavioral disturbances in middle cerebral artery-occluded rats.
    Yamamoto M, Tamura A, Kirino T, Shimizu-Sasamata M, Sano K.
    Eur J Pharmacol; 1991 May 17; 197(2-3):117-23. PubMed ID: 1915564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.